   body {font-family: 'Open Sans', sans-serif;}

table { width: 100%; } table caption { text-align: left; } table thead th { text-align: left; } table td { text-align: left; padding: 6px; width: 100%; border-bottom-style: ridge; border-bottom-width: thin; border-bottom-color: Gray; } table th { text-align: left; padding: 6px; white-space: nowrap; border-bottom-style: ridge; border-bottom-width: thin; border-bottom-color: Gray; }

# Dopamine (Intropin) Pharmacology and Notes

**Refractory CHF**: initial dose: 0.5 to 2 mcg/kg/min**For Renal-** (1-5 mcg/kg/min) increases urine output per dopamine receptors**For Cardiac** (2-10 mcg/kg/min) increases systolic and pulse pressure via myocardial contractility (usually start at 5mcg/kg/min) via beta 1 receptors**For Cardiac and Vasocontriction** (10-20 mcg/kg/min)

* * *

**Cardiac life support** (initial): 2 to 5 mcg/kg/min - titrate to effect.  
Increase by 1-4 mcg/kg/minute at 10 to 30 minute intervals .  
If dosages >20-30 mcg/kg/minute are needed -consider a levophed or Epi drip a more direct-acting pressor may be more beneficial  
0.5 to 2 mcg/kg/min-dopa  
2-10-dopa/beta  
\>10-primarily alpha.

* * *

  

**Dopamine (Intropin))Notes  
**precursor of norepinephrine stimulates dopaminergic, Alpha and Beta adrenergic receptors (little or no beta-2 effect) Comes pre-mixed  
400mg/500ml Bag (800mcg/ml)  
800mg/250ml Bag (3200 mcg/ml)  
400mg/250ml Bag (1600mcg/ml)  
**Low dose-2-5mcg/kg/min** \- For Renal-causes more splanchnic dilatation, improving renal blood flow (urine output) per dopamine receptors  
**Medium Dose 5-10mcg/kg/min** ï¿½Cardiac-Beta 1 receptors start to predominate  
**High Dose- 10-20mcg/kg/min**\-Vasoconstriction (Alpha 1) becomes more prevalent **.** Always use large IV-preferably a central line to avoid a nasty infiltration- Extravasation necrosis (treat with phentolamine)

* * *

  
**Metabolism  
**Metabolized in the liver, kidney, and plasma by MAO and catechol-O-methyltransferase to inactive compounds  
25% of dose is taken up in the adrenergic nerve terminals where it is hydrolyzed to norepinephrine.  
**Elimination** Half-life 2 mins, 80% excreted in urine within 24 hours  
**Onset** Within 5 min.**Duration** Less than 10 min.**  
Adverse effects  
**Infiltrated IV-Extravasation necrosis (treat with phentolamine)  
asthma exacerbation  
hypotension,  
tachycardia  
nausea  
vomiting  
vasoconstriction  
conduction abnormalities.

* * *

**Contraindications**

Pheochromocytoma (Adrenal Gland Tumor)  
allergic to any ingredient in Dopamine Taking droxidopa or have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the past 21 days uncorrected tachyarrhythmias ventricular fibrillation  
allergy to corn/corn products (dextrose solutions)  
uncorrected tachyarrhythmias  
ventricular fibrillation  
allergy to corn/corn products (dextrose solutions)

* * *

**Dopamine Infiltration Treatment**  
To prevent sloughing and necrosis in ischemic areas, the area should be infiltrated as soon as possible with 10 to 15 mL of saline solution containing from 5 to 10 mg of phentolamine mesylate